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Globally, the number of people affected by coronavirus disease 2019 (COVID-19) is rapidly 
increasing. In most (>80%), the illness is relatively mild and can be self-managed out of 
hospital. However, in about 20% the illness causes respiratory compromise severe enough to 
require hospital admission.[1] Patients with severe and critical disease need full active 
treatment. This may include oxygen for hypoxaemia and ventilatory support, along with 
optimal management of complications, e.g. super-imposed bacterial infection, and any 
underlying co-morbidities, e.g. chronic obstructive pulmonary disease, congestive heart 
failure. To date, no antiviral agent has shown to be effective in treating the disease.[2]  
Patients with severe disease not considered suitable for escalation to intensive care, i.e. those 
who are frail or have multiple co-morbidities, are at very high risk of dying, with an 
estimated death rate of 15–22%.[3, 4] We have a moral obligation to provide good symptom 
control to prevent avoidable suffering. Thus, comprehensive care of the patient with COVID-
19 requires identification of patients at increased risk of dying, who would benefit from a 
parallel approach to management. This encompasses optimal symptom management for those 
with severe disease but who will survive, and expert symptom management and end of life 
care for those that are deteriorating and in their last days–hours of life.  The aim of this 
editorial is to provide a succinct informative overview to guide respiratory healthcare 
professionals on the frontline.  
Symptom relief 
The most common symptoms are breathlessness, cough and fever. 
Breathlessness (5–65%)[5-9]: The highest incidence will be in those with severe disease and 
is expected in those actively dying. The primary driver of breathlessness is the viral lung 
infection causing an interstitial pneumonia with a reduction in lung diffusing capacity; in 
some patients this evolves to Acute Respiratory Distress Syndrome (ARDS). The experience 
of breathlessness is also influenced by emotional, environmental, cultural and social factors, 
and optimal management requires a holistic approach. These include non-pharmacological 
and pharmacological approaches. Non-pharmacological approaches include breathing 
techniques.[10] Although an electric hand-held fan directed at the face is helpful in other 
settings [10, 11],  this is not recommended in COVID-19 because of the theoretical infection 
control risk of spreading infected droplets. As an alternative, use of facial cooling with wet 
wipes (binning after each use, as for tissues) can be tried.  
Pharmacological approaches are the mainstay of management for patients with severe disease 
who are likely to have rapidly worsening breathlessness at rest. Morphine is the opioid of 
choice.[12, 13] However, alternative strong opioids can be used. Short-acting oral opioids, 
given as required, may suffice when breathlessness is mild. However, in severe disease or at 
the end of life, continuous infusions of parenteral opioids are preferable, maximising 
symptom management whilst reducing nurse and community staff time, use of resource 
limited protective equipment and exposure. Use of the parenteral route is also preferred for 
speed of onset of action and ability to rapidly titrate doses. If there is distressing 
breathlessness at rest, opioids should be combined with an anxiolytic sedative, e.g. 
midazolam (Table 1). Rapid titration of benzodiazepines may be needed. The primary role of 
oxygen is to correct hypoxaemia. There is a suggestion it may help breathlessness in severe 
hypoxaemia [14],  but not when mild or absent.[15] In a comatose/unresponsive dying 
patient, oxygen can be titrated down with goal of discontinuation, while concurrently 
managing symptoms of breathlessness.[16] 
Cough (70–80%)[5-9]: Potential mechanisms in viral respiratory infection and ARDS include 
inflammation, epithelial damage, mucus impaction and neuro-modulatory changes 
(heightened cough reflex sensitivity).[17] Evidence for effective management of acute cough 
is limited.[18, 19] Adequate hydration and regular small sips of water may help.[20] 
However, because of the likely concurrent need for breathlessness management, strong 
opioids are likely to be more pragmatic in practice. High-level evidence is limited [21,22], 
but relatively low doses of long-acting oral morphine (5-10mg twice daily) are helpful in 
refractory chronic cough (Table 1).[21] Although these patients do not have chronic cough, 
opioids may be helpful in reducing cough alongside treatment for breathlessness. [22] 
Delirium: Delirium is common in medical illness and almost universal in the last days–hours 
of life. Non-pharmacological management includes regular orientation, avoiding 
constipation, treating pain, maintaining oxygenation and avoiding urinary retention.[23] 
When ineffective and where the delirium is causing significant distress, pharmacological 
therapy with an antipsychotic (such as haloperidol) should be considered; in the context of 
severe breathlessness and at the end of life, a sedative anxiolytic such as levomepromazine or 
midazolam should be used (See Table 1) to allow rapid titration if needed.   
Anxiety: Anxiety secondary to breathlessness, social isolation and fear is likely to be present 
to some degree in all patients with COVID-19.  Severely ill patients may be particularly 
distressed, due to the looming possibility that their situation may rapidly worsen and that they 
may die, potentially compounded by the loss of support from their families, who are not 
allowed to visit, and receiving care from health professionals in personal protective 
equipment.  Non-pharmacological methods such as relaxation therapy and breathing 
exercises are effective in mild anxiety but if patients are significantly anxious or have severe 
disease, the focus should be on pharmacological management. For severe disease and if 
people are actively dying, benzodiazepines are likely to be most effective.[24] Optimal relief 
may necessitate increasing depths of sedation rapidly in the last days–hours or of life, 
particularly when associated with severe breathlessness (See Table 1). 
 
Psychological support  
Families of patients with COVID-19 face a significant psychological burden that is often 
magnified by family members themselves being in isolation or under financial strain. Often, 
more than one member of the same family may be infected and in hospital. Visiting is likely 
to also be limited/prohibited. There may also be guilt over possibly transmitting the infection 
to their loved one. The quality of the dying experience and lack of preparation for the death 
are both predictors of complicated grief. Health professionals should communicate with 
families regularly and where possible facilitate communication between patients and their 
families utilising virtual technology.[25]Information leaflets should be provided for both 
patients and family members. If family members are unable to visit, leaflets should be 
emailed where possible. See Figure 1 and 2 for example leaflets that can be used and 
supplementary files for downloadable editable WORD documents.  
Information needs and parallel planning 
In patients with severe disease, there is a need for parallel planning- hoping for the best but 
preparing for the worst. Therefore, there is an urgent need for early and honest discussions at 
the time of hospitalisation/diagnosis of COVID-19 for those with a high risk of severe illness 
and death.  Health professionals should focus on advance care planning with open and honest 
conversations as to what is important to the individual, to inform treatment escalation 
planning including resuscitation status, should they deteriorate.  
Health professionals should acknowledge the distress of this complex and unique situation, 
and be compassionate, respectful and empathic. We must explain that active resuscitative 
care and symptom management do not need to be mutually exclusive, where resources allow. 
The focus of care should be iterative, adapting to worsening clinical status or patient 
expressed altered goals of care. Importantly, healthcare professionals need to be proactive in 
the provision of information and ensure that if there is a significant possibility that the patient 
will die, that this is addressed with both the patient and family (Table 1).  
Spiritual Care 
The importance of spirituality in coping with uncertainty, severe disease and at the end of life 
is recognised.[26]  Spiritual wellbeing offers some protection against end of life despair in 
those for whom death is imminent.[26] Hospital chaplains provide spiritual care that helps 
patients facing serious illness better cope with their symptoms and prognosis. Most hospitals 
around the world will have chaplains/representatives from all faiths in the chaplaincy office. 
The family of the patient or the dying patient may want to see speak to someone about their 
impending death. Chaplain interventions, whether or not religious, focused on comforting the 
patient and improving his or her well-being in the context of both his or her spiritual pain and 
critical illness should be explored with all patients and carers.[27] It is important that the 
spiritual care needs of those who are not represented by chaplaincy available or who are not 
religious, should also be addressed.  
Conclusion 
COVID-19 patients with severe disease/at the end of life have an equal right to care. 
Receiving adequate symptom control is a basic human right and we have a fundamental duty 
to relieve suffering and provide the best care with the available resources regardless of the 
chances of survival. 
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Table 1 Example clinical guidelines for the management of the severe/dying COVID-19 patient   
Symptom/need Clinical indication Recommendation 
Distressing 
breathlessness at rest 
  Stat dose morphine 2.5mg SC/IV + midazolam 2.5mg SC/IV (reduce both to 1.25mg if eGFR <30 or elderly)  
 
If continuous infusion is available: 
 Morphine 10mg + midazolam 10mg CSCI/ IV over 24hrs OR morphine 5mg + midazolam 5mg CSCI/IV over 24hrs (if eGFR <30 or in the elderly).  
 In addition, prescribe morphine 2.5mg + midazolam 2.5mg SC/IV p.r.n. 4 hourly (1.25mg for both if eGFR<30 or in the elderly) 
If continuous infusion is not available:  
 Morphine 2.5mg SC/IV + midazolam 2.5mg SC/IV 4 hourly (1.25mg for both if eGFR<30 or in the elderly). 
 In addition, prescribe morphine 2.5mg SC/IV + midazolam 2.5mg SC/IV p.r.n. 4 hourly (1.25mg for both if eGFR<30 or in the elderly) 
 
Monitor patients receiving opioids for undesirable effects, particularly nausea and vomiting, and constipation. Depending on individual circumstances, prescribe a 
regular or p.r.n anti-emetic and a regular laxative. 
Anxiety Mild   Relaxation techniques and breathing exercises 
Moderate/severe   Midazolam 2.5mg SC/IV p.r.n (1.25mg for both if eGFR<30 or in the elderly) 
If needed regularly, consider a CSCI/IV infusion (starting dose midazolam 10mg /24hr- reduce to 5mg if eGFR<30 or elderly) 
Cough  If continuous infusion is available: 
 Morphine 10mg CSCI/ IV over 24hrs (5mg CSCI/IV if eGFR<30 or elderly) 
If continuous infusion is not available:  
 Morphine 2.5mg SC/IV SC/IV 4 hourly (1.25mg for both if eGFR<30 or in the elderly). 
 
Monitor patients receiving opioids for undesirable effects, particularly nausea and vomiting, and constipation. Depending on individual circumstances, prescribe a 
regular or p.r.n anti-emetic and a regular laxative. 
Fever   Paracetamol 1g QDS PO/IV (avoid NSAIDs unless end of life) 
Delirium Mild confusion  Orientation to time and place 
Delirium with distress  Orientation to time and place, if ineffective haloperidol 1-10mg SC/IV in 1-3 divided doses over 24hrs; maximum 10mg/day (halve all doses in elderly; 
maximum 5mg/day) 
Delirium/agitation at end of 
life 
 Stat dose levomepromazine 25 mg SC/IV or midazolam 5mg (reduce to levomepromazine 12.5mg and midazolam 2.5mg if eGFR<30 or elderly).  
If needed regularly, consider CSCI/IV infusion (either levomepromazine 50mg or midazolam 15mg /24hr- reduce to levomepromazine 25mg or midazolam 7.5mg 
(if eGFR<20 or elderly).  
NB May need to titrate rapidly if ongoing agitation. Where on both opioid and sedative - titrate the sedative up for terminal delirium NOT the opioid 
Communication Patients  “I understand that this is an emotional time, anyone would be scared/anxious...it is normal to be worried and scared.”  
 “We do not think recovery from this illness is possible and [you/they] may die over the next [few hours / days / short weeks] .”  
 “I am very sorry that you cannot have your loved ones around you, but as you can see, you are here with us, you are not alone, we will stay with you.”  
Family  “What concerns you the most?” “It’s understandable you feel this way / This must be really hard for you / It is upsetting.” “Who is around to support you?” “Is 
there something we can do to help?” 
 “We are concerned about the condition of your [relative] and think that they are ‘sick enough to die’”  
Further information/resources available at: https://www.vitaltalk.org/guides/covid-19-communication-skills/, SIGN delirium guidance  https://www.sign.ac.uk/sign-157-delirium 
CSCI- continuous subcutaneous infusion; SC – subcutaneous;  IV – intravenous; PO – per oral; BD – twice daily; GFR – glomerular filtration rate 
Insert Figure 1 here 
Figure 1: Example information sheet for COVID-19 patients admitted to hospital (downloadable WORD document available in supplementary files) 
 
Insert Figure 2 here 
Figure 2: Example information sheet for familes/friends of COVID-19 patients admitted to hospital (downloadable WORD document available in 
supplementary files)
1. WHO-China Joint Mission. Report of the WHO-China Joint Mission on Coronavirus Disease 
2019 (COVID-19) 2020  [cited 2020 17 March 2020]; Available from: 
https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-
report.pdf 
2. Rubin EJ, Baden LR, Morrissey S. Audio Interview: New Research on Possible Treatments for 
Covid-19. New England Journal of Medicine 2020: 382(12): e30. 
3. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X. Clinical course and risk 
factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort 
study. The Lancet 2020. 
4. Guan W-j, Liang W-h, Zhao Y, Liang H-r, Chen Z-s, Li Y-m, Liu X-q, Chen R-c, Tang C-l, Wang T. 
Comorbidity and its impact on 1,590 patients with COVID-19 in China: A Nationwide Analysis. 
medRxiv 2020. 
5. Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, Liu L, Shan H, Lei C-l, Hui DS. Clinical 
characteristics of coronavirus disease 2019 in China. New England Journal of Medicine 2020. 
6. Yang X, Yu Y, Xu J, Shu H, Liu H, Wu Y, Zhang L, Yu Z, Fang M, Yu T. Clinical course and 
outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, 
retrospective, observational study. The Lancet Respiratory Medicine 2020. 
7. Xu X-W, Wu X-X, Jiang X-G, Xu K-J, Ying L-J, Ma C-L, Li S-B, Wang H-Y, Zhang S, Gao H-N. 
Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside 
of Wuhan, China: retrospective case series. Bmj 2020: 368. 
8. Wang L, Gao Y-h, Zhang G-J. The clinical dynamics of 18 cases of COVID-19 outside of 
Wuhan, China. European Respiratory Journal 2020. 
9. Zhang S, Li H, Huang S, You W, Sun H. High-resolution CT features of 17 cases of Corona Virus 
Disease 2019 in Sichuan province, China. European Respiratory Journal 2020. 
10. Higginson IJ, Bausewein C, Reilly CC, Gao W, Gysels M, Dzingina M, McCrone P, Booth S, 
Jolley CJ, Moxham J. An integrated palliative and respiratory care service for patients with advanced 
disease and refractory breathlessness: a randomised controlled trial. The Lancet Respiratory 
Medicine 2014: 2(12): 979-987. 
11. Gysels M, Reilly CC, Jolley CJ, Pannell C, Spoorendonk F, Bellas H, Madan P, Moxham J, 
Higginson IJ, Bausewein C. How does a new breathlessness support service affect patients? European 
Respiratory Journal 2015: 46(5): 1515-1518. 
12. Ekström M, Nilsson F, Abernethy AA, Currow DC. Effects of opioids on breathlessness and 
exercise capacity in chronic obstructive pulmonary disease. A systematic review. Annals of the 
American Thoracic Society 2015: 12(7): 1079-1092. 
13. Ekström M, Bajwah S, Bland JM, Currow DC, Hussain J, Johnson MJ. One evidence base; 
three stories: do opioids relieve chronic breathlessness? Thorax 2018: 73(1): 88-90. 
14. Bruera E, de Stoutz N, Velasco-Leiva A, Schoeller T, Hanson J. Effects of oxygen on dyspnoea 
in hypoxaemic terminal-cancer patients. The Lancet 1993: 342(8862): 13-14. 
15. Abernethy AP, McDonald CF, Frith PA, Clark K, Herndon II JE, Marcello J, Young IH, Bull J, 
Wilcock A, Booth S. Effect of palliative oxygen versus room air in relief of breathlessness in patients 
with refractory dyspnoea: a double-blind, randomised controlled trial. The Lancet 2010: 376(9743): 
784-793. 
16. Campbell ML, Yarandi H, Dove-Medows E. Oxygen is nonbeneficial for most patients who are 
near death. Journal of pain and symptom management 2013: 45(3): 517-523. 
17. Atkinson SK, Sadofsky LR, Morice AH. How does rhinovirus cause the common cold cough? 
BMJ open respiratory research 2016: 3(1): e000118. 
18. Malesker MA, Callahan-Lyon P, Ireland B, Irwin RS, Adams TM, Altman KW, Azoulay E, Barker 
AF, Birring SS, Blackhall F. Pharmacologic and nonpharmacologic treatment for acute cough 
associated with the common cold: CHEST Expert Panel Report. Chest 2017: 152(5): 1021-1037. 
19. Hill AT, Gold PM, El Solh AA, Metlay JP, Ireland B, Irwin RS, Adams TM, Altman KW, Azoulay 
E, Barker AF. Adult outpatients with acute cough due to suspected pneumonia or influenza: CHEST 
Guideline and Expert Panel Report. Chest 2019: 155(1): 155-167. 
20. Mitchell SAC, Garrod R, Clark L, Douiri A, Parker SM, Ellis J, Fowler SJ, Ludlow S, Hull JH, 
Chung KF. Physiotherapy, and speech and language therapy intervention for patients with refractory 
chronic cough: a multicentre randomised control trial. Thorax 2017: 72(2): 129-136. 
21. Fuller RW, Karlsson JA, Choudry NB, Pride NB. Effect of inhaled and systemic opiates on 
responses to inhaled capsaicin in humans. J Appl Physiol 1988: 65(3): 1125-1130. 
22. Morice AH, Millqvist E, Bieksiene K, Birring SS, Dicpinigaitis P, Ribas CD, Boon MH, Kantar A, 
Lai K, McGarvey L. ERS guidelines on the diagnosis and treatment of chronic cough in adults and 
children. European Respiratory Journal 2020: 55(1). 
23. Network. SIG. Risk reduction and Management of delirium 2019  [cited March 2020]; 
Available from: https://www.sign.ac.uk/sign-157-delirium  
24. Practice guideline for the treatment of patients with panic disorder. Work Group on Panic 
Disorder. American Psychiatric Association. Am J Psychiatry 1998: 155(5 Suppl): 1-34. 
25. Lobb EA, Kristjanson LJ, Aoun SM, Monterosso L, Halkett GKB, Davies A. Predictors of 
Complicated Grief: A Systematic Review of Empirical Studies. Death Studies 2010: 34(8): 673-698. 
26. McClain CS, Rosenfeld B, Breitbart W. Effect of spiritual well-being on end-of-life despair in 
terminally-ill cancer patients. The lancet 2003: 361(9369): 1603-1607. 
27. Berning JN, Poor AD, Buckley SM, Patel KR, Lederer DJ, Goldstein NE, Brodie D, Baldwin MR. 
A novel picture guide to improve spiritual care and reduce anxiety in mechanically ventilated adults 
in the intensive care unit. Annals of the American Thoracic Society 2016: 13(8): 1333-1342. 
 
 
EUROPEAN
LUNG
FOUNDATION
This information leaflet was compiled by Dr Sabrina Bajwah (Cicely Saunders Institute, King’s 
College London) with extensive input from co-authors and patient/carer groups to accompany 
the ERJ editorial “Managing the supportive care needs of those affected with COVID-19”. 
Please cite this editorial as follows:
Bajwah S, Wilcock A, Towers R, Costantini M, Bausewein C, Simon ST, Bendstrup E, Prentice 
W, Johnson MJ, Currow DC, Kreuter M, Wells AU, Birring SS, Edmonds P, Higginson IJ (2020). 
Managing the supportive care needs of those affected by COVID-19. ERJ: doi (TO BE INSERTED)
Produced in April 2020
1www.europeanlung.org
Information for patients admitted to hospital 
with COVID-19
Alongside active measures to treat the disease, it is important that we reduce the distress that you may experience. 
This is done through treating your symptoms:
• Breathlessness can be improved by keeping as calm and relaxed as possible, but if your breathlessness gets worse, 
we will use medication to help with this. Morphine is the most common medicine used. Although usually given 
for pain, morphine can be used safely to relieve the feeling of breathlessness. 
• Cough can also be relieved by morphine. 
• Anxiety can be common; medicines used to help with this symptom include lorazepam and midazolam. 
• Restlessness can occur if you develop a fever and this can be controlled using paracetamol.
All medicines will be given regularly and when you need them. If you become unable to swallow the medicine, it can 
be given as an injection either through a vein or under the skin. 
In the most serious cases, COVID-19 can severely affect the lungs, stopping them from working normally. A ventilator 
may be used to move air into and out of the lungs to help you breathe. You may need to be on a ventilator for several 
days until your lungs are able to work properly again.  
What treatment will I receive? 
Can I decide how I am treated?
How can I communicate with those important to me?
COVID-19 can cause minor to serious illness. 
You have been admitted to hospital with COVID-19 so that we can monitor your breathing. Your breathing may 
need to be supported with oxygen and sometimes with a ventilator (artificial breathing). We also want to help 
with any symptoms you may have. 
This leaflet will explain what treatment you may receive, and what support will be available. 
You should talk to the doctors about what is important to you. You may have preferences about how and when certain 
actions should be taken. For example, when to start ventilation or whether to restart the heart if it stops. The doctors 
will take your views into consideration together with your medical condition. Difficult decisions about your medical 
care may need to be made quickly if you become unwell so it is important that you let the medical team know what 
you want them to do. If you are unsure, please discuss this with a member of the medical team.  
There are strict isolation rules in place both outside and inside the hospital, which means that you may not be allowed 
visitors. Any visitors will have to wear personal protective equipment (otherwise known as PPE – face masks etc.). 
Where possible, ward staff will try to help you communicate with people important to you by telephone or video 
calls. Please let the ward staff know if you are happy for them to share information in this way and if there are specific 
people you wish to be kept informed. 
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Can I get additional support?
We understand that this is a difficult time. You may want to talk about how you feel. Please ask a member of the ward 
staff to contact any of the following support services that are available to you:
List of local hospital support services:
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Information for family/friends of those admitted
to hospital with COVID-19
Alongside active measures to treat the disease, it is important that we reduce the distress that they may experience. 
This is done through treating symptoms:
• Breathlessness can be improved by keeping as calm and relaxed as possible, but if breathlessness gets worse, we 
will use medication to help with this. Morphine is the most common medicine used. Although usually given for 
pain, morphine can be used safely to relieve the feeling of breathlessness. 
• Cough can also be relieved by morphine. 
• Anxiety can be common; medicines used to help with this symptom include lorazepam and midazolam. 
• Restlessness can occur if a fever develops and this can be controlled using paracetamol.
All medicines will be given regularly and when needed. Medicines can be given as an injection either through a vein 
or under the skin if necessary. 
In the most serious cases, COVID-19 can severely affect the lungs, stopping them from working normally. A ventilator 
may be used to move air into and out of the lungs to help with breathing. A ventilator may be used for several days 
until the lungs are able to work properly again.
What treatment will they receive? 
Making decisions
How can I communicate with them?
COVID-19 can cause minor to serious illness. 
Your family member/friend has been admitted to hospital with COVID-19 so that we can monitor their breathing. 
Their breathing may need to be supported with oxygen and sometimes with a ventilator (artificial breathing). We 
will also help with any symptoms they may have. 
This leaflet will explain what treatment they may receive, and what support will be available to them and you. 
Difficult decisions about the care your family member/friend receives may need to be made rapidly by the medical 
teams. For example, when to start ventilation or whether to restart the heart if it stops. Please let the medical team 
know whether you have had these discussions with your family member/friend already and what they said. If you are 
unsure, then please discuss with one of the medical team. Many of the conversations with the doctors and nurses 
will have to take place on the telephone and we recognise that this will be difficult. Please make sure we have your 
correct contact details and let the ward staff know if you wish to be kept informed.
There are strict isolation rules in place both outside and inside the hospital, which means that you may not be allowed 
to visit. If visiting the hospital, you will have to wear personal protective equipment (otherwise known as PPE – face 
masks etc.). Where possible, ward staff will help you communicate by telephone or video calls.  
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Can I get additional support?
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